التفاصيل البيبلوغرافية
| العنوان: |
Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial |
| المؤلفون: |
Harpreet S. Bajaj (9250266), Richard M. Bergenstal (6254405), Andreas Christoffersen (10151925), Melanie J. Davies (7155500), Amoolya Gowda (10151928), Joakim Isendahl (292774), Ildiko Lingvay (6805151), Peter A. Senior (5954285), Robert J. Silver (10151929), Roberto Trevisan (499060), Julio Rosenstock (4963318) |
| سنة النشر: |
2021 |
| المجموعة: |
Smithsonian Institution: Digital Repository |
| مصطلحات موضوعية: |
Clinical Sciences not elsewhere classified, Basal Insulins, Basal Therapy, Efficacy, Glycemic Control, Randomized Controlled Trial, Phase 2 Studies, Safety, Continuous Glucose Monitoring |
| الوصف: |
OBJECTIVE Insulin icodec (icodec) is a novel once-weekly basal insulin analog. This trial investigated two approaches for switching to icodec versus once-daily insulin glargine U100 (IGlar U100) in people with type 2 diabetes receiving daily basal insulin and ≥1 oral glucose-lowering medication. RESEARCH DESIGN AND METHODS This multicenter, open-label, treat-to-target phase 2 trial randomized (1:1:1) eligible basal-insulin-treated (total daily dose 10–50 U) people with type 2 diabetes (HbA 1c 7.0–10.0% [53.0–13.3 mmol/mo]) to icodec with an initial 100% loading dose (where only the first dose was doubled; icodec LD), icodec with no loading dose (icodec NLD) or IGlar U100 for 16 weeks. Primary endpoint was percent time in range (TIR; 3.9–10.0 mmol/L [70–180 mg/dL]) during weeks 15 and 16, measured using continuous glucose monitoring. Key secondary endpoints included HbA 1c , adverse events (AEs) and hypoglycemia. RESULTS Estimated mean TIR during weeks 15 and 16 was 72.9% (icodec LD; n = 54), 66.0% (icodec NLD; n = 50) and 65.0% (IGlar U100; n = 50), with a statistically significant difference favoring icodec LD versus IGlar U100 (7.9%-points, 95% CI 1.8 to 13.9%). Mean HbA 1c reduced from 7.9% (62.8 mmol/mol) at baseline to 7.1% ([54.4 mmol/mol] icodec LD) and 7.4% ([57.6 mmol/mol] icodec NLD and IGlar U100); incidences and rates of AEs and hypoglycemic episodes were comparable. CONCLUSIONS Switching from daily basal insulin to once-weekly icodec was well tolerated and provided effective glycemic control. Loading dose use when switching to once-weekly icodec significantly increased percent TIR during weeks 15 and 16 versus once-daily IGlar U100, without increasing hypoglycemia risk. |
| نوع الوثيقة: |
still image |
| اللغة: |
unknown |
| العلاقة: |
https://figshare.com/articles/figure/Switching_to_Once-Weekly_Insulin_Icodec_Versus_Once-Daily_Insulin_Glargine_U100_in_Type_2_Diabetes_Inadequately_Controlled_on_Daily_Basal_Insulin_A_Phase_2_Randomized_Controlled_Trial/14043746Test |
| DOI: |
10.2337/figshare.14043746.v2 |
| الإتاحة: |
https://doi.org/10.2337/figshare.14043746.v2Test |
| حقوق: |
CC BY-NC-SA 4.0 |
| رقم الانضمام: |
edsbas.372AD9CF |
| قاعدة البيانات: |
BASE |
